Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum, and Pediatrics (FrSADP3)

计划摘要 该提案“在孕期、产后和儿科治疗药物滥用障碍方面处于领先地位” (FrSADP3)“要求在NIDA的研究教育计划中首次续签。主要的理由是 代表不足的少数族裔(URM)临床医生和临床研究人员太少，临床和 调查物质使用(SU)和滥用(SA)，特别是物质滥用的研究计划 妊娠、产后和儿科疾病(SAD)；新的URM学员太少了 在SADP3领域内从事临床和临床研究工作。许多创新包括优化 怀孕期间和怀孕后关注的SAD话题的深度、广度和范围以及领导力和 土著美国人的参与。我们的目标是培训、指导、提供有意义的研究 体验并帮助启动SAD临床医生和临床科学家的临床职业生涯(R25临床 实习生)。FrSADP3包括Pi和PIT的项目总监Gerald Schatten博士，以及Co-I Aimee McRae- 克拉克，药学博士，BCPP(成瘾研究领导者)，与Theresa Cronan，博士，在SDSU(辅导员， 心理学家，URM和妇女健康)，Calvin Simerly，博士，PIT(项目协调员)，和Evan 斯奈德，医学博士，SBP(上瘾新生儿专家)。它由一个科学顾问委员会监督，40%的人 是URM的教职员工。五个具体目标：I.年度FrSADP3高级动手实验室课程，在 我们提供概念教育、专家指导的讨论和研究的URM机构 对患有SAD或有SAD风险的孕妇及其新生儿进行必要的方法培训， 幼儿和儿童；自我给药的相关动物；和 缓解SADP3痛苦的治疗策略，以及可在以下网址获得的研究资源 奈达和其他地方。对孕期药物使用和滥用障碍的指导性研究， 产后和儿科，由参与者与任何FrSADP3教职员工共同发起。三. 鼓励学员制定更长期的职业规划，温和探索他们自我确定的职业选择， 特别是在他们加入NIDA-NIH临床和研究队伍的可能性内。四、揭开神秘面纱 负责任的研究行为(RCR)中不断变化的监管监督要求，以确保充分 遵守美国国立卫生研究院的指导。V.不偏不倚、量化的独立评价以跟踪 参与者的职业生涯。那么，R25的S的目标是提供技能发展、指导成瘾的课程 研究和持续的职业支持，带来全面、复杂的临床和 应对当前孕期成瘾挑战的翻译策略，设计 为未来提供更好的治疗方法，并启动和维持药物滥用方面的成功职业生涯， 怀孕、儿科及相关领域。通过这样做，FrSADP3将继续推进 最有前途的临床科学家和临床医生，并敏锐地确保NIDA员工队伍的完全多样性。

PROGRAM SUMMARY This proposal “Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum and Pediatrics (FrSADP3)” requests its first renewal within NIDA’s Research Education Program. The primary rationale is that there are too few underrepresented minority (URM) clinicians and clinical researchers, too few clinical and research programs investigating substance use (SU) and abuse (SA), and especially, substance abuse disorders (SAD) during pregnancy, postpartum, and in pediatrics (P3); there are far too few new URM trainees for clinical and clinical research careers within the SADP3 fields. Many innovations include optimizing the depth, breadth, and scope of SAD topics of concern during and following pregnancy and the leadership and participation of Indigenous Americans. Our objectives are to train, mentor, provide meaningful research experiences for and help launch the clinical careers of SAD Clinicians and Clinical Scientists (R25 Clinical Trainees). FrSADP3 includes PI and Program Director Gerald Schatten, PhD, at Pitt and Co- I Aimee McRae- Clark, PharmD, BCPP (Addiction Research Leader), with Theresa Cronan, PhD, at SDSU (Facilitator, Psychologist, URM and Women’s Health), Calvin Simerly, PhD, at Pitt (Program Coordinator), and Evan Snyder, MD, PhD, at SBP (Addiction Neonatologist). It is overseen by a Scientific Advisory Board, 40% who are URM faculty. Five Specific Aims: I. Annual FrSADP3 advanced hands-on lab courses, offered at a URM Institution at which we provide conceptual education, expert guided discussions and research training in the methods necessary for studying pregnant people with or at risk for SAD and their neonates, toddlers, and children; relevant animals that self-administer drugs; and the mechanisms of and therapeutic strategies to alleviate the suffering from SADP3, along with research resources available at NIDA and elsewhere. II. Mentored Research into substance use and abuse disorders during pregnancy, postpartum and pediatrics, launched by the participant, together with any FrSADP3 faculty member. III. Encourage trainees’ longer-term Career Planning and gently exploring their self-identified career choices, particularly within the possibilities of them joining NIDA-NIH’s clinical and research workforce. IV. Demystify the changing regulatory oversight requirements in Responsible Conduct for Research (RCR) to ensure full compliance with the NIH’s guidance. V. Unbiased, Quantitative Independent Evaluations to track participants’ careers. The R25’s goals, then, are to provide courses in skills development, mentored addiction research, and ongoing career support resulting in comprehensive, sophisticated training in clinical and translational strategies for addressing the current challenges in addiction during pregnancy, for designing better therapies for the future, and for launching and sustaining successful careers in substance abuse, pregnancy, pediatrics, and related fields. In so doing, FrSADP3 will continue to advance the careers of the most promising clinical scientists and clinicians, with sensitivity for ensuring full diversity in the NIDA workforce.